1. Home
  2. ALIS vs UNCY Comparison

ALIS vs UNCY Comparison

Compare ALIS & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ALIS

Calisa Acquisition Corp Ordinary shares

N/A

Current Price

$8.70

Market Cap

85.9M

Sector

N/A

ML Signal

N/A

Logo Unicycive Therapeutics Inc.

UNCY

Unicycive Therapeutics Inc.

N/A

Current Price

$3.56

Market Cap

100.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ALIS
UNCY
Founded
2024
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
85.9M
100.6M
IPO Year
2024
2021

Fundamental Metrics

Financial Performance
Metric
ALIS
UNCY
Price
$8.70
$3.56
Analyst Decision
Strong Buy
Analyst Count
0
10
Target Price
N/A
★ $28.40
AVG Volume (30 Days)
10.8K
★ 1.0M
Earning Date
01-01-0001
11-24-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ 0.04
N/A
Revenue
N/A
★ $675,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$10,044.55
P/E Ratio
$209.88
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.27
$3.33
52 Week High
$14.91
$8.74

Technical Indicators

Market Signals
Indicator
ALIS
UNCY
Relative Strength Index (RSI) 39.63 42.19
Support Level $7.70 $3.34
Resistance Level $10.17 $4.18
Average True Range (ATR) 0.87 0.21
MACD 0.03 0.04
Stochastic Oscillator 55.62 40.00

Price Performance

Historical Comparison
ALIS
UNCY

About ALIS Calisa Acquisition Corp Ordinary shares

Calisa Acquisition Corp is a blank check company with the purpose of effecting a merger, asset acquisition, stock exchange, stock purchase, reorganization, or similar business combination.

About UNCY Unicycive Therapeutics Inc.

Unicycive Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and commercializing therapies to address unmet medical needs, with a primary focus on kidney disease. The company is advancing two key product candidates: oxylanthanum carbonate (OLC), a phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis, and UNI-494, a drug candidate for the treatment of acute kidney injury.

Share on Social Networks: